A New Approach to Immunotherapy
Immunotherapy has emerged as one of the most exciting trends in oncology in the last decade, ushering in a new era of approaches to cancer therapy and offering hope to patients even in late stages of this disease. Despite clinical advances in broadening adoption of immunotherapies, many cancer patients still relapse or fail to respond to novel immunotherapies. At iSTAT, we seek to overcome resistance to immunotherapy by developing drugs to target molecules critically implicated in tumor immune suppression, lifting current barriers and stimulating highly efficacious immune responses against various human cancers.
The iSTAT Mission
STAT3 transcription factor is an oncogenic and tolerogenic protein, which is activated in cancer cells as well in immune cells in the tumor microenvironment. As the master regulator of cancer immune resistance, STAT3 is highly attractive molecular target for cancer immunotherapy but it still remains undruggable. Recognizing this unmet therapeutic need, iSTAT Therapeutics is focused on the clinical development of first-in-class, immunogenic oligonucleotides to block STAT3 while simultaneously inducing potent T cell-mediated antitumor immune responses. Pre-clinical models have demonstrated efficacy of such bi-functional STAT3 inhibitors in models of non-Hodgkin's Lymphoma and Acute Myeloid Leukemia, in addition to solid tumors such as melanoma, head and neck, bladder, colon and prostate cancers.
Get in Touch
We’re happy to hear from you. Contact us today to learn more about our business and how you can benefit from working with us.
139 N. Garfield Pl
Monrovia, CA, USA 91016
1 (909) 518-9216
1 (626) 205-9190